Physician profile
Thomas Auxter
NPI 1902865470
$4,653.52
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,787 · 2020: $828 · 2023: $38.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $469.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $458.12 | 2019 | |
| Amarin Pharma, INC. | $299.26 | 2019-2020 | |
| Lilly USA, LLC | $274.84 | 2019-2020 | |
| Pfizer INC. | $261.60 | 2019-2020 | |
| Amgen INC. | $255.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $238.30 | 2019-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $218.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.78 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $168.86 | 2019 | |
| Merck Sharp & Dohme LLC | $162.07 | 2019 | |
| Abbvie INC. | $138.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.29 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $109.19 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $96.68 | 2019 | |
| Astellas Pharma US INC | $91.80 | 2019 | |
| Sunovion Pharmaceuticals INC. | $79.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $76.45 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $42.54 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $35.36 | 2019 | |
| Antares Pharma, INC. | $27.11 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $23.71 | 2019 | |
| Boston Scientific Corporation | $16.69 | 2023 | Wavewriter Alpha Prime 16 |
| Celgene Corporation | $16.34 | 2019 | |
| Currax Pharmaceuticals LLC | $14.71 | 2020 | |
| Genentech USA, INC. | $12.20 | 2019 | |
| Assertio Therapeutics, INC. | $11.89 | 2019 | |
| Shire North American Group INC | $11.46 | 2019 | |
| Horizon Therapeutics Plc | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Auxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.